Mendelian Randomization Study of ACLY and Cardiovascular Disease | Zendy

Brian A. Ference | Zendy; Kausik K. Ray | Zendy; Alberico L. Catapano | Zendy; Thatcher B. Ference | Zendy; Stephen Burgess | Zendy; David Neff | Zendy; Clare OliverWilliams | Zendy; Angela Wood | Zendy; Adam S. Butterworth | Zendy; Emanuele Di Angelantonio | Zendy; John Danesh | Zendy; John J.P. Kastelein | Zendy; Stephen J. Nicholls | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Mendelian Randomization Study of ACLY and Cardiovascular Disease

Author(s) -

Brian A. Ference,

Kausik K. Ray,

Alberico L. Catapano,

Thatcher B. Ference,

Stephen Burgess,

David Neff,

Clare OliverWilliams,

Angela Wood,

Adam S. Butterworth,

Emanuele Di Angelantonio,

John Danesh,

John J.P. Kastelein,

Stephen J. Nicholls

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1806747

Subject(s) - atp citrate lyase , medicine , mendelian randomization , endocrinology , lyase , cholesterol , hmg coa reductase , lipoprotein , reductase , odds ratio , hydroxymethylglutaryl coa reductase , bioinformatics , enzyme , biochemistry , biology , gene , genotype , citrate synthase , genetic variants

ATP citrate lyase is an enzyme in the cholesterol-biosynthesis pathway upstream of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the target of statins. Whether the genetic inhibition of ATP citrate lyase is associated with deleterious outcomes and whether it has the same effect, per unit decrease in the low-density lipoprotein (LDL) cholesterol level, as the genetic inhibition of HMGCR is unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research